Drug delivery means

• US 20070225264A1
• Filed: 03/20/2007
• Published: 09/27/2007
• Est. Priority Date: 03/20/2006
• Status: Active Grant

• Current Assignee: Therasyn Sensors Inc.
• Original Assignee: Mary P. Mccourt
• Inventors: McCourt, Mary P.
• Granted Patent: US 9,119,782 B2
• Time in Patent Office: Days
• US Class Current: 514/182
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 38/1761 Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
• CPC Class Codes: A61K 38/45 Transferases (2)
• CPC Class Codes: A61K 38/482 Serine endopeptidases (3.4.21)
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/28 Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61K 9/1272 with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids with cholesterol as the only non-phosphatidyl surfactant A61K9/127; lipids as modifying agent A61K47/543
• CPC Class Codes: A61K 9/1277 Processes for preparing; Proliposomes
• CPC Class Codes: C12Y 207/11001 Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
• CPC Class Codes: C12Y 304/21078 Granzyme A (3.4.21.78)
• CPC Class Codes: C12Y 304/21079 Granzyme B (3.4.21.79)

Abstract

The invention broadly comprises a chemical composition including a plurality of cholesteryl esters arranged to form a vesicle. In several embodiments, all of the plurality of cholesteryl esters have a same molecular length, which in some embodiments provides a vesicle having a generally smooth outer surface, while in other embodiments, a portion of the plurality of cholesteryl esters have different molecular lengths, which in some embodiments provides a vesicle having a generally irregular outer surface. In yet further embodiments, a shape of the vesicle is selected from the group consisting of spherical, oval, disc-like, tubular and polyhedral shapes, and in yet other embodiments, a wall of the vesicle is selected from the group consisting of a monolayer and a bilayer. In still further embodiments, the chemical composition further includes a polyethylene glycol coat of mixed polymer size. In some embodiments, the plurality of cholesteryl esters include at least two different cholesteryl esters, and in some of these embodiments, the at least two different cholesteryl esters are selected from the group consisting of: cholesteryl myristate, cholesteryl laurate, cholesteryl dodeconate, cholesteryl palmitate, cholesteryl arachidonate, cholesteryl behenate, cholesteryl linoleate, cholesteryl linolenate, cholesteryl oleate and cholesteryl stearate.

Claims

1. A chemical composition comprising:

a plurality of cholesteryl esters arranged to form a vesicle.

2. The chemical composition of claim 1 wherein all of said plurality of cholesteryl esters have a same molecular length.

3. The chemical composition of claim 2 wherein said vesicle has a generally smooth outer surface.

4. The chemical composition of claim 1 wherein a portion of said plurality of cholesteryl esters have different molecular lengths.

5. The chemical composition of claim 4 wherein said vesicle has a generally irregular outer surface.

6. The chemical composition of claim 1 wherein a shape of said vesicle is selected from the group consisting of spherical, oval, disc-like, tubular and polyhedral shapes.

7. The chemical composition of claim 1 wherein a wall of said vesicle is selected from the group consisting of a monolayer and a bilayer.

8. The chemical composition of claim 1 further comprising a polyethylene glycol coat of mixed polymer size.

9. The chemical composition of claim 1 wherein said plurality of cholesteryl esters comprise at least two different cholesteryl esters.

10. The chemical composition of claim 9 wherein said at least two different cholesteryl esters are selected from the group consisting of:

cholesteryl myristate, cholesteryl laurate, cholesteryl dodeconate, cholesteryl palmitate, cholesteryl arachidonate, cholesteryl behenate, cholesteryl linoleate, cholesteryl linolenate, cholesteryl oleate and cholesteryl stearate.

11. The chemical composition of claim 1 where said composition is clear dispersed in both hydrophilic and hydrophobic systems.

12. The chemical composition of claim 11 where said composition is smaller than wavelengths of visible light.

13. A method of delivering a drug to a cell comprising the steps of:

a) combining a pharmaceutically effective amount of at least one drug with at least one cholestosome; and

,

b) utilizing said at least one cholestosome to introduce said drug to the cell.

14. The method of delivering a drug according to claim 13 further comprising the step of:

c) depositing said at least one drug within said cell.

15. A method of manufacturing at least one cholestosome comprising the steps of:

a) mixing at least one cholesteryl ester in a first solvent to form a composition;

b) mixing said composition of step a) with a second solvent until said at least one cholesteryl ester, said first solvent and said second solvent form a homogenous dispersion; and

,

c) evaporating said first solvent leaving said at least one cholestosome in said second solvent.

16. A method of manufacturing a drug delivery system comprising the steps of:

a) mixing at least one cholesteryl ester in a first solvent to form a composition;

b) mixing said composition of step a) and at least one drug in a pharmaceutically effective amount in a second solvent until said at least one cholesteryl ester, said first solvent, said at least one drug and said second solvent form a homogenous dispersion; and

,

c) evaporating said first solvent leaving at least one cholestosome in said second solvent, wherein said at least one drug is combined with said at least one cholestosome.

17. The method of claim 16 where the drug is contained within the cholestosome.

18. The method of manufacturing a drug delivery system according to claim 16 wherein said first solvent is a non-polar solvent and said second solvent is a polar solvent.

19. A drug delivery system manufactured by the steps comprising:

a) mixing at least one cholesteryl ester in a first solvent to form a composition;

b) mixing said composition of step a) and at least one drug in a pharmaceutically effective amount in a second solvent until said at least one cholesteryl ester, said first solvent, said at least one drug and said second solvent form a homogenous dispersion; and

,

c) evaporating said first solvent leaving at least one cholestosome in said second solvent, wherein said at least one drug is combined with said at least one cholestosome.

20. The method of claim 19 wherein the drug is contained within the cholestosome.